SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001714899-24-000216
Filing Date
2024-11-06
Accepted
2024-11-06 16:17:01
Documents
67
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q dnli-20240930.htm   iXBRL 10-Q 1537560
2 EX-31.1 exhibit311q32024.htm EX-31.1 9896
3 EX-31.2 exhibit312q32024.htm EX-31.2 9916
4 EX-32.1 exhibit321q32024.htm EX-32.1 5559
5 EX-32.2 exhibit322q32024.htm EX-32.2 5688
  Complete submission text file 0001714899-24-000216.txt   6799511

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20240930.xsd EX-101.SCH 44184
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnli-20240930_cal.xml EX-101.CAL 59959
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20240930_def.xml EX-101.DEF 217952
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20240930_lab.xml EX-101.LAB 599411
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20240930_pre.xml EX-101.PRE 415865
70 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20240930_htm.xml XML 846422
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38311 | Film No.: 241431226
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)